Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUILT-88: Combination Immunotherapy Plus Chemotherapy in Pancreatic Cancer
NCT04390399Phase 2Active, not recruiting
- Sponsor
- ImmunityBio, Inc.
- Start
- Jul 2020
- Primary completion
- Oct 2025
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, aldoxorubicin, PD-L1 t-haNK in pancreatic cancer (PC), sponsored by ImmunityBio, Inc.. Started Jul 2020; status: active, not recruiting.
02
Drugs
nogapendekin alfa inbakiceptaldoxorubicinPD-L1 t-haNK
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04390399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390399.